FY25 Results Announcement
| Stock | Integral Diagnostics Ltd (IDX.ASX) |
|---|---|
| Release Time | 26 Aug 2025, 9:25 a.m. |
| Price Sensitive | Yes |
Integral Diagnostics Reports FY25 Results
- Solid operating revenue growth with improved Operating EBITDA margin
- Strong Operating Diluted EPS growth of 32.9%
- Business performing in line with expectations, merger integration on track and annualised synergies $4.0m above initial expectations
- Balance sheet remains strong with reduced leverage
Integral Diagnostics Limited (ASX: IDX) announced its financial results for the year ended 30 June 2025 (FY25). The company reported consolidated revenue and other income of $628.0m, up 33.7%, and operating EBITDA of $126.5m, up 38.3%, including $7.0m of merger synergies. The operating EBITDA margin improved to 20.1%, up from 19.5% in the prior year. Operating NPAT grew 77.4% to $31.6m, and operating diluted EPS increased by 32.9%. The company's balance sheet remained strong, with net debt to operating EBITDA of 2.6x (2.4x pro forma including annualised synergies), down from 2.8x at 31 December 2024. The merger integration with Capitol Health is proceeding on plan, with annualised synergies now expected to be $14.0m, significantly exceeding the initial target of at least $10.0m. The company declared a fully franked final dividend of 4.0 cents per share, bringing the full-year dividend to 6.5 cents per share.
Revenue growth and Operating EBITDA margin is expected to expand further over time, driven by the inclusion of $14.0m of annualised synergies, ramp-up of new greenfield clinics and brownfield investments, and scale benefits including increased use of teleradiology and procurement efficiencies. Group FY26 replacement and growth capex is expected to be between $45.0m to $55.0m.
IDX as a specialist, high-quality provider of diagnostic services is strategically well positioned to benefit from positive industry fundamentals and grow services strongly going forward. The company's focus in FY26 and beyond will be to drive organic earnings growth, accelerate the use of teleradiology, digital and AI, drive its ESG strategy, lead through its values, and complete the IDX and Capitol merger integration, including ongoing realisation of additional synergies.